Update on Anti-angiogenic Treatment for Malignant Gliomas

Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition

(2013) Y. Piao et al.   CLINICAL CANCER RESEARCH

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges

(2013) Gazanfar Rahmathulla et al.   OncoTargets and Therapy

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

(2012) Shota Tanaka et al.   Nature Reviews Clinical Oncology

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas

(2011) Katsuyuki Shirai et al.   Journal of Oncology

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Bevacizumab does not increase the risk of remote relapse in malignant glioma

(2010) Antje Wick et al.   ANNALS OF NEUROLOGY

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas

(2009) Michael L.H. Wong et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Antiangiogenic strategies for treatment of malignant gliomas

(2009) Andrew S. Chi et al.   Neurotherapeutics

Angiogenesis as a Therapeutic Target in Malignant Gliomas

(2009) A. S. Chi et al.   ONCOLOGIST

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

(2008) Sith Sathornsumetee et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Time course of imaging changes of GBM during extended bevacizumab treatment

(2008) Suchitra Ananthnarayan et al.   JOURNAL OF NEURO-ONCOLOGY

Novel anti-angiogenic therapies for malignant gliomas

(2008) Andrew D Norden et al.   LANCET NEUROLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE